PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
187.54%
Cash & equivalents growing 187.54% while TRAW's declined -22.68%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
187.23%
Below half of TRAW's -22.68%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
168.93%
Below half of TRAW's -22.50%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-20.60%
1.25-1.5x TRAW's -17.14%. Bruce Berkowitz notes a significant push to expand capacity faster than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-16.19%
Similar yoy growth to TRAW's -16.67%. Walter Schloss finds parallel expansions in non-current assets.
No Data
No Data available this quarter, please select a different quarter.
164.96%
Below half of TRAW's -22.44%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-45.35%
Above 1.5x TRAW's -4.22%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
-33.08%
Higher Short-Term Debt Growth compared to TRAW's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
43.64%
Higher Deferred Revenue (Current) Growth compared to TRAW's zero value, indicating better performance.
-68.51%
Less than half of TRAW's 44.24%. David Dodd sees fewer expansions in other current obligations.
-61.96%
Less than half of TRAW's 4.92%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-61.96%
Less than half of TRAW's 1.64%. David Dodd sees far fewer liability expansions relative to competitor.
19.13%
Higher Common Stock (Book Value) Growth compared to TRAW's zero value, indicating worse performance.
-3.37%
0.75-0.9x TRAW's -4.19%. Bill Ackman questions if competitor reinvests profits more robustly.
-26.34%
Less than half of TRAW's -230.77%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
955.36%
Below half TRAW's -48.31%. Michael Burry sees potential underperformance in building shareholder capital.
164.96%
Below half TRAW's -22.44%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-33.08%
Higher Total Debt Growth compared to TRAW's zero value, indicating worse performance.
-197.28%
Less than half of TRAW's 22.68%. David Dodd sees better deleveraging or stronger cash buildup than competitor.